

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
BEUVINK ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/001849

FILED: 22 FEBRUARY 2005

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: P53 WILD-TYPE AS BIOMARKER FOR THE TREATMENT WITH  
MTOR INHIBITORS IN COMBINATION WITH A CYTOTOXIC  
AGENT

**MS: PCT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUBMISSION OF SEQUENCE LISTING  
INCLUDING STATEMENT OF VERIFICATION


\ Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same, and include no new matter.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7909

Date: *August 22, 2006*

  
Thomas R. Savitsky  
Attorney for Applicants  
Reg. No. 31,661